Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: Effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy

Prostate

Volumn 66, Issue 15, 2006, Pages 1653-1663

  Rayburn, Elizabeth R ^a   Wang, Wei ^a   Zhang, Zhuo ^a   Li, Mao ^a   Zhang, Ruiwen ^a,b,c   Wang, Hui ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemosensitization; Chemotherapy; CpG; Immunomodulatory oligonucleotide; TLR9

Indexed keywords

DOCETAXEL; GEMCITABINE; IMMUNOMODULATING OLIGONUCLEOTIDE; LIPOFECTIN; MESSENGER RNA; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN PC 3; CELL SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; ISOGRAFT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES; PHOSPHATIDYLETHANOLAMINES; PROSTATIC NEOPLASMS; RNA, MESSENGER; TAXOIDS; TOLL-LIKE RECEPTOR 9;

EID: 33750463425     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20485     Document Type: Article

References (49)

1. Leading Sites of New Cancer Cases and Deather-2006 Estimates. American Cancer Society, Inc., Surveillance Research. 2006. Available online: http://www.cancer.org/docroot/MED/content/downloads/ MED_1_1x_CFF2006_Leading_Sites_New_ Cases_Deaths_Estimates.asp
2. Nelson WG. Agents in development for prostate cancer prevention. Expert Opin Investig Drugs 2004;13:1541-1554.
3. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-887.
4. Petrylak DP. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 2005;65 (5 Suppl):3-7.
5. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004;92:287-295.
6. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
7. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000;68:455-463.
8. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
9. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
10. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004;16:17-22.
11. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release 2004;97:1-17.
12. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: Review of the literature and potential applications in malignant glioma. Front Biosci 2003;8:115-127.
13. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs 2003;4:686-690.
14. Wang H, Rayburn E, Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogues as novel anticancer therapeutics. Curr Pharm Des 2005;11:2889-2907.
15. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, Menard S, Pratesi G. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004;40:1275-1281.
16. Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg AM. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: Decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev 2002;12:155-164.
17. Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong Y-P, Song SS, Tang JX, Sullivan T, Agrawal S. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci USA 2005;102:6925-6930.
18. Zhao Q, Yu D, Agrawal S. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett 1999;9:3453-3458.
19. Zhao Q, Yu D, Agrawal S. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg Med Chem Lett 2000;10:1051-1054.
20. Agrawal S, Kandimalla ER. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets 2001;1:197-209.
21. Yu D, Kandimalla D, Bhagat L, Tang JY, Cong Y, Tang J, Agrawal S. 'Immunomers'-novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002;30:4460-4469.
22. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Immunostimulatory activity of CpG oligonucleotides containing nonionic methylphosphonate linkages. Bioorg Med Chem 2001;9:2803-2808.
23. Yu D, Kandimalla ER, Zhao Q, Bhagat L, Cong Y, Agrawal S. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg Med Chem 2003;11:459-464.
24. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett 2001;11:2263-2267.
25. Yu D, Kandimalla ER, Cong Y, Tang J, Tang JY, Zhao Q, Agrawal S. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alky-linker substitutions: Role of nucleosides in the flanking sequences. J Med Chem 2002;45:4540-4548.
26. Kandimalla ER, Yu D, Zhao Q, Agrawal S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: Structure- immunostimulatory activity relationships. Bioorg Med Chem 2001;9:807-813.
27. Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, Tang JX, Tang JY, Knetter CF, Lien E, Agrawal S. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci USA 2003;100:14303-14308.
28. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172:S6-S11.
29. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2005;26:1170-1181.
30. Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, Wang H, Huang P, Zhang R, Agrawal S. Divergent synthetic nucleotide motif recognition pattern: Design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 2003;31: 2393-2400.
31. Li Y, Kandimalla ER, Yu D, Agrawal S. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. Int Immunopharmacol 2005;5:981-991.
32. Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms. Prostate 2003;54:194-205.
33. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003;100:11636-11641.
34. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 1999;96:13989-13994.
35. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-9242.
36. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco B, Rossini A, Selleri S, Rumio C, Menard S, Balsari A. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005;65:6388-6393.
37. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-3330.
38. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 2005;116:992-997.
39. Jahrsdorfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005;77:378-387.
40. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105-3114.
41. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol 2004;24:901-908.
42. Roberts TL, Sweet MJ, Hume DA, Stacey KJ. Cutting edge: Species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 2005;174:605-608.
43. Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: In vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun 2002;297:83-90.
44. Ren J, Zheng L, Chen Q, Li H, Zhang L, Zhu H. Coadministration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth. J Transl Med 2004;2:29.
45. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001;167:4878-4886.
46. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28:2045-2054.
47. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005;28:886-892.
48. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005;6:1.
49. Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000;19:3325-3336.